Breaking News, Collaborations & Alliances

Dicerna Earns KHK Milestone

Selects second oncology candidate

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Kyowa Hakko Kirin Co., Ltd. (KHK) has selected a second therapeutic oncology candidate from its research collaboration with Dicerna Pharmaceuticals, triggering a $5 million milestone payment to Dicerna.   The research collaboration and license agreement with KHK has a potential value of $1.4 billion for the research, development and commercialization of Dicer substrate siRNA (DsiRNA) pharmaceuticals and drug delivery systems for gene targets with therapeutic potential in oncology. DsiRNA deliver...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters